van den Reek, J.M.P.A.;
van Lümig, P.P.M.;
Janssen, M.;
Schers, H.J.;
Hendriks, J.C.M.;
van de Kerkhof, P.C.M.;
Seyger, M.M.B.;
de Jong, E.M.G.J.
Increased incidence of squamous cell carcinoma of the skin after long‐term treatment with azathioprine in patients with auto‐immune inflammatory rheumatic diseases
You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Increased incidence of squamous cell carcinoma of the skin after long‐term treatment with azathioprine in patients with auto‐immune inflammatory rheumatic diseases
Contributor:
van den Reek, J.M.P.A.;
van Lümig, P.P.M.;
Janssen, M.;
Schers, H.J.;
Hendriks, J.C.M.;
van de Kerkhof, P.C.M.;
Seyger, M.M.B.;
de Jong, E.M.G.J.
imprint:
Wiley, 2014
Published in:Journal of the European Academy of Dermatology and Venereology
Description:
<jats:title>Abstract</jats:title><jats:p><jats:bold>Background </jats:bold> Auto‐immune inflammatory rheumatic diseases (AIRD) are often successfully treated with the immunosuppressant azathioprine for years. Treatment with azathioprine has been proven to increase the risk of non‐melanoma skin cancer (NMSC) in transplant patients and possibly in patients with inflammatory bowel disease as well. Little is known about the risk of NMSC in AIRD patients treated with azathioprine.</jats:p><jats:p><jats:bold>Objectives </jats:bold> The aim of this study is to determine the incidence of NMSC in patients with AIRD treated with azathioprine for at least 1 year, as compared with the general Dutch population.</jats:p><jats:p><jats:bold>Methods </jats:bold> Data were extracted from a historical cohort of patients with AIRD in a tertiary care centre. We compared the incidence to an age‐matched control population and analysed risk factors for NMSC with univariate logistic regression.</jats:p><jats:p><jats:bold>Results </jats:bold> Fifty‐nine patients were analysed. No patients were diagnosed with basal cell carcinoma and four patients with a single squamous cell carcinoma (SCC). Patients with SCC had a higher cumulative dose of azathioprine (≥500 g: OR 30.0 [95% CI 2.6–345.1]) and longer treatment duration (≥11 years: OR 13.5 [95% CI 1.3–143.6]). The risk of SCC compared with the general Dutch population was increased (standardized incidence ratio of 16.0 [95% CI 0.3–31.7]).</jats:p><jats:p><jats:bold>Conclusions </jats:bold> In this cohort of patients with AIRD treated with azathioprine for at least 1 year, the risk of SCC was increased, as compared with the general population. An individual cumulative dose of at least 500 g azathioprine and a treatment duration of at least 11 years were quantified as risk factors.</jats:p>